| Literature DB >> 32210603 |
Vittorio Mazzarello1, Elisabetta Gavini2, Giovanna Rassu2, Matthew Gavino Donadu1,2, Donatella Usai1, Gabriella Piu1, Valeria Pomponi1, Federica Sucato3, Stefania Zanetti1, Maria Antonia Montesu3.
Abstract
BACKGROUND: Acne is a frequent adolescent disease characterized by inflammatory and non-inflammatory lesions whose topical treatment very often presents adverse phenomena such as irritation or resistance to antibiotics that reduce the patient's compliance. The purpose of this study is to compare a commercial product (Acnatac gel) based on clindamycin-tretinoin (CTG) with a galenic compound containing 2 essential oils (Myrtus communisL. and Origanum vulgare) and tretinoin (MOTC) to evaluate its anti-acne effectiveness and action on the microclimate of the skin.Entities:
Keywords: acne; essential oils; non-invasive skin analysis
Year: 2020 PMID: 32210603 PMCID: PMC7073433 DOI: 10.2147/CCID.S236956
Source DB: PubMed Journal: Clin Cosmet Investig Dermatol ISSN: 1178-7015
Susceptible Test to Different Antibiotics
| S. aureus | P. aeruginosa | P. aeruginosa | S. epidermidis | S. epidermidis | S. aureus | S. aureus | S. epidermidis | |
|---|---|---|---|---|---|---|---|---|
| Amikacin | S | S | S | S | S | S | // | S |
| Amox/Kclav | R | R | R | R | R | R | R | R |
| Amp/Sulbactam | R | R | R | R | R | R | R | R |
| Ampicillin | R | R | R | R | R | R | R | R |
| Aztreonam | s | s | s | s | s | s | // | s |
| Cefepime | S | S | S | S | S | S | // | S |
| Cefpodoxime | R | R | R | R | R | R | R | R |
| Ceftazidime | S | S | S | S | S | S | // | S |
| Ceftriaxone | R | R | R | R | R | R | R | R |
| Cefuroxime | R | R | R | R | R | R | R | R |
| Chloramphenicol | R | R | R | R | R | R | R | R |
| Colistin | S | S | S | S | // | S | // | S |
| Doripenem | S | S | S | S | S | S | R | S |
| Fosfomycin | R | R | R | R | R | R | R | R |
| Imipenem | S | S | S | S | S | S | R | S |
| Meropenem | S | S | S | S | S | S | // | S |
| Norfloxacin | R | R | R | R | R | R | R | R |
| Pip/Tazo | S | S | S | S | R | S | // | S |
| Piperacillin | S | S | S | S | R | S | // | S |
| Tetracyclin | R | R | R | R | R | R | R | R |
| Tobramycin | S | S | S | S | S | S | // | S |
| Trime/Sulfa | R | R | R | R | R | R | R | R |
Notes: R= Resistant; S= Sensible; //= not tested.
Demographic Characteristics of Patients
| Group A | Group B | |
|---|---|---|
| n = 30 | n = 30 | |
| Male | 15 (50%) | 15 (50%) |
| Female | 15 (50%) | 15 (50%) |
| Age (mean and SD) | 14–36 | 14–35 |
| Acne Severity Index | 21.71 ± 5.92 | 20 ± 6.41 |
Efficacy of MOTC (Myrtus communisL., Origanum vulgare and Treotinoine Cream), CTG (Clindamycin and Tretinoin Gel) in the Modification of Biophysical Parameters
| to | t15 | t30 | |
|---|---|---|---|
| Erythema Index Measurement of Acne ic Papules | |||
| MOTC p-value | 596.2 ± 69.6 | 571.5 ± 96.40* | 566.6 ± 93.6 |
| CTG p-value | 637.7± 32.6 | 635.8± 24.8 | 623.4± 29.7 |
| Erythema Index Measurement of Cheek Healthy Skin | |||
| MOTC p-value | 554.5±56,8,6 | 563.7 ± 68.5* | 572.6 ± 75.3** |
| CTG p-value | 578.3± 58.6 | 594.9± 74.8 | 602.4± 66.3 |
| Sebum Measurement of Cheek Healthy Skin | |||
| MOTC p-value | 99.5 ± 42.8 | 105.3 ± 53.9 | 105.7 ± 54.5 |
| CTG p-value | 123.6± 59.9 | 103.3± 61.9 | 103.8± 62.4 |
| pH Measurement of Cheek Healthy Skin | |||
| MOTC p-value | 5.227 ± 0.57 | 5.382 ± Q57 | 5.305 ± 0.55 |
| CTG p-value | 6.263± 3.12 | 5.5 ±0.5 | 5.6± 1.15 |
| TEWL Measurement of Cheek Healthy Skin | |||
| MOTC p-value | 18.58± 6.40 | 20.76 ± 5.55* | 21.71 ± 5.95 |
| CTG p-value | 13.27± 5.37 | 15.55± 4.80 | 18 ± 1.86 |
Notes: Mean with SD difference in erythema index, sebum, pH and TEWL (transepidermal water loss) from baseline to days 15 and 30. Inter-group comparison: *P ≤ 0.05, **P ≤ 0.01.
Efficacy of MOTC (Myrtus communisL., Origanum vulgare and Tretinoin Cream), CTG (Clindamycin and Tretinoin Gel) in the Reduction of Different Type Lesions
| to | t15 | t30 | |
|---|---|---|---|
| CN Measurement | |||
| MOTC p-value | 20.2 ± 12.7 | 13.1 ± 8.25 | 11 ± 8.25 |
| CTG p-value | 39.3 ± 30.8 | 28.4 ± 17.2 | 14.3± 19.3 |
| PPN Measurement | |||
| MOTC p-value | 15.1 ± 9.58 | 12.2 ± 4.82 | 8.8± 5.26 |
| CTG p-value | 17.3 ± 16.9 | 15.6 ± 14.7 | 12.9± 17.5 |
| PSN Measurement | |||
| MOTC p-value | 7.4 ± 4.40 | 3.3 ± 1.56 | 3.9 ± 2.37 |
| CTG p-value | 11.9 ± 8.88 | 5.1 ± 3.21 | 5.5± 4.14 |
| TLC Measurement | |||
| MOTC p-value | 42.7 ± 22.9 | 28.6 ± 10.2 | 23.7 ± 10.4 |
| CTG p-value | 64.6 ± 42.8 | 46.3 ± 24.2 | 31.3± 22.7 |
| ASI Measurement | |||
| MOTC p-value | 34.9 ± 19.0 | 22.0 ± 4.90 | 19.3 ± 8.30 |
| CTG p-value | 49.9 ± 28.1 | 32.2 ± 17.6 | 27.1± 22.5 |
Notes: Mean with SD difference in number of comedones (CN), papules (PPN), pustules (PSN), acne severity index (ASI) and total lesion count (TLC) from baseline to days 15 and 30.
Figure 1Clinical efficacy of three formulations in the reduction of lesions and erythema after 15 days of treatment.